Company news

Inoviq Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test

March 31, 2022

Update on Legal Proceedings and BARD1 Autoantibody Program

March 27, 2022

Brazilian Patent Issued for Lung & Colorectal Cancer

February 22, 2022

Appendix 4C & Quarterly Activities Report

January 30, 2022

AGM Presentation

November 29, 2021

BARD1 Appoints New CSO

September 16, 2021

BARD1 Share Purchase Plan Completed Oversubscribed

August 22, 2021

Proof-of-Concept for SubB2M ELISA-Based Ovarian Cancer Test

August 16, 2021

BARD1 lodges spp and options prospectus

July 30, 2021

BARD1 Collaborator Uni of QLD Announces Ovarian Cancer Data

July 28, 2021

Updated Investor Presentation

July 23, 2021

BARD1 $15m Placement to Accelerate Cancer Diagnostic Program

July 22, 2021

BARD1 Investor Presentation

July 7, 2021

BARD1 Autoantibody Test Results for Ovarian Cancer Published

June 28, 2021

Update on Legal Proceedings

June 4, 2021

BARD1 Demonstrates Feasibility of SubB2M-Based IHC Test

May 24, 2021

BARD1 EXO-NET Exosome Data Presented at ISEV2021 Conference

May 18, 2021

BARD1 Launches its RUO EXO-NET Product

May 17, 2021

Appendix 4C and Quarterly Activities Report

April 30, 2021

Positive Results from the BARD1 Autoantibody Assay

April 28, 2021

BARD1 Signs Option Agreement for Type 3C Diabetes Test

April 12, 2021

Positive Results Evaluation of EXO-NET in Pancreatic Cancer

March 15, 2021

Appendix 4D and Half-year financial report

February 26, 2021

Commencement of Legal Proceedings Against BARD1

February 23, 2021

Excellent SubB2M Breast Cancer Test Data

February 14, 2021

Outstanding SubB2M Ovarian Cancer Test Data

February 10, 2021

AGM & CEO Presentations and Chairmans Transcript

November 26, 2020

BARD1 Gains New High-volume Customer for its hTERT Test

November 22, 2020

Successful BARD1 Kit Evaluation

September 22, 2020

BARD1 Awarded BTB Funding to Develop Breast Cancer Test

September 2, 2020

Appendix 4E and Annual Report to Shareholders

August 24, 2020

European Patent Validated

August 10, 2020

Quarterly Business Update & Appendix 4C

July 29, 2020

BARD1 completes Sienna acquisition

July 28, 2020

Quarterly Activities Report & Appendix 4C

April 28, 2020

BARD1 Signs Contract with Griffith University

April 1, 2020

Half Yearly Report and Accounts

February 25, 2020

Appendix 4C Quarterly Cashflow Report

January 29, 2020

Appendix 4C - quarterly

October 29, 2019

Phase 3 Assay Development Milestone Reached

October 7, 2019

Quarterly Business Update and Appendix 4C

July 30, 2019

Completion of Capital Raising Package

July 11, 2019

Closure of Entitlement Offer and Shortfall Notification

July 9, 2019

Progress on Assay Development Program

July 1, 2019

Offer Document

June 18, 2019

Capital Raising and Board Changes

June 17, 2019

European Patent validated

June 2, 2019

R&D Tax Incentive Refund

May 27, 2019

U.S. Patent Issued

April 30, 2019

Response to ASX Price and Volume Query

April 1, 2019

← Newer news releases · Older news releases →

Decks

The 5 newest of 31 decks. Every deck is listed under its year.